• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.

作者信息

Li Xiao Xiao

机构信息

Department of Respiratory and Critical Care, First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Am J Ther. 2021 Jul 8;29(2):e269-e271. doi: 10.1097/MJT.0000000000001231.

DOI:10.1097/MJT.0000000000001231
PMID:33416243
Abstract
摘要

相似文献

1
Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.低剂量阿帕替尼治疗奥希替尼耐药后伴有Kras突变的晚期肺腺癌：一例报告
Am J Ther. 2021 Jul 8;29(2):e269-e271. doi: 10.1097/MJT.0000000000001231.
2
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.曲美替尼克服了 EGFR 突变型肺癌脑膜转移模型中 KRAS-G12V 诱导的奥希替尼耐药。
Cancer Sci. 2021 Sep;112(9):3784-3795. doi: 10.1111/cas.15035. Epub 2021 Jul 22.
3
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。
J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.
4
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.在一名患有EGFR L718Q突变的非小细胞肺癌患者中使用阿法替尼解决对奥希替尼治疗的耐药性
Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.
5
Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.携带EGFR突变和BRAF V600E的肺腺癌对奥希替尼和维莫非尼联合用药有反应，可克服奥希替尼耐药性。
Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11.
6
Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.奥希替尼治疗后，1例伴有神经内分泌分化的肺腺癌患者出现NOTCH2-NTRK1融合
Clin Lung Cancer. 2021 Mar;22(2):e157-e159. doi: 10.1016/j.cllc.2020.10.003. Epub 2020 Oct 15.
7
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.携罕见 EGFR L747P 突变的非小细胞肺癌对吉非替尼和奥希替尼（AZD9291）均表现出内在耐药性：一例报告。
Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.
8
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.利用下一代测序技术探索非小细胞肺癌患者二线奥希替尼的耐药机制及其预后意义。
Eur J Cancer. 2021 May;148:202-210. doi: 10.1016/j.ejca.2021.01.052. Epub 2021 Mar 18.
9
Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.一名EGFR突变型肺腺癌患者在对奥希替尼产生获得性耐药后，肿瘤先转变为鳞状细胞癌，后又转变为肉瘤样癌：病例报告
Clin Lung Cancer. 2021 Jul;22(4):e536-e541. doi: 10.1016/j.cllc.2020.06.026. Epub 2020 Jul 5.
10
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.EML4-ALK融合作为奥希替尼的耐药机制及其通过奥希替尼和阿来替尼成功治疗：病例报告及文献综述
Clin Lung Cancer. 2020 Nov;21(6):e597-e600. doi: 10.1016/j.cllc.2020.05.016. Epub 2020 May 23.